A collection of 1,985 lots of normal serum albumin (NSA) and 1,361 lots of plasma protein fraction (PPF) prepared between 1958 and 1974 were tested for the presence of hepatitis B surface antigen (HBsAg). Twenty-one percent of NSA lots and 71 per cent of PPF lots were HBsAg-positive by radioimmunoassay. There was considerable variation in frequency of HBsAg-positive lots among the 17 different manufacturers of NSA and the six manufacturers of PPF. In general, those lots prepared from volunteer donor plasma and placental material demonstrated lower rates of HBsAg-positivity than those prepared from commercial donor plasma. A striking decrease in the prevalence of HBsAg-positive lots of both NSA and PPF occurred during the period 1971 to 1973, coincident with the onset of routine screening of all plasma for HBsAg. Although NSA and PPF can be HBsAg-positive, they probably do not transmit type B hepatitis. Serologic tests for HBsAg and antibody to HBsAg revealed that albumin products prepared from infectious, icterogenic plasma were infectious prior to pasteurization, but that they no longer transmitted type B hepatitis after heat treatment at 60 C for ten hours.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1046/j.1537-2995.1976.16276155108.x | DOI Listing |
Biomed Res Int
January 2025
Department of Biology, College of Natural & Computational Sciences, University of Gondar, Gondar, Ethiopia.
Hepatitis and human immunodeficiency virus (HIV) are major public health issues in developing countries, including Ethiopia. These viruses can be transmitted from mother to child during birth or through contact with contaminated blood. In many areas of Ethiopia, viral hepatitis and HIV infections are significant health concerns for pregnant women.
View Article and Find Full Text PDFObjective: To analyze the clinical effectiveness of Entecavir (ETV) and Tenofovir Disoproxil Fumarate (TDF) Tablets for the treatment of chronic hepatitis B (CHB).
Methods: Clinical data from 100 CHB patients admitted to our hospital from April 2022 to April 2024 were retrospectively reviewed. Of these, 45 cases in the control group received ETV, and 55 cases in the research group received TDF tablets.
Neurology
February 2025
Department of Preventive Medicine and Epidemiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain.
Background And Objectives: Hepatitis B vaccination (HBV) requires 6 months to complete and is recommended for patients with multiple sclerosis (PWMS), particularly those who are candidates for anti-CD20 therapy. However, limited data exist on HBV immunogenicity in PWMS receiving disease-modifying therapies (DMTs) and the impact of starting anti-CD20 therapy during immunization. We aimed to evaluate HBV immunogenicity in PWMS starting anti-CD20 therapy during vaccination, focusing on the number of doses received before anti-CD20 initiation.
View Article and Find Full Text PDFClin Nephrol Case Stud
January 2025
Department of Medicine.
Minimal change disease (MCD) accounts for 10 - 15% of idiopathic nephrotic syndromes in adults. Chronic hepatitis C virus (HCV) infection is rarely ascribed as a cause of MCD and was previously associated with interferon-based therapy. MCD in treatment-naïve chronic HCV infection is extremely rare, with only 3 cases reported in the literature.
View Article and Find Full Text PDFWorld J Gastroenterol
January 2025
Department of Radiology, Kindai University, Faculty of Medicine, Osakasayama 589-8511, Osaka, Japan.
Background: Focal nodular hyperplasia (FNH)-like lesions are hyperplastic formations in patients with micronodular cirrhosis and a history of alcohol abuse. Although pathologically similar to hepatocellular carcinoma (HCC) lesions, they are benign. As such, it is important to develop methods to distinguish between FNH-like lesions and HCC.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!